Pascal Soriot refuses to be drawn, however, on reports AZ could move its main stock market listing across the Atlantic
AstraZeneca’s chief executive has hailed the “vital importance of the US” to the British drugmaker, days after announcing a $50bn (£37bn) investment in the country at a time when Donald Trump’s threatened tariffs are looming over the sector.
Pascal Soriot, who leads Britain’s most valuable company, refused to comment, however, on recent media reports that AstraZeneca is considering moving its main stock market listing from the UK to the US.
Soriot told reporters on Tuesday he had met a large number of members of Trump’s administration, including the commerce secretary, Howard Lutnick.
He said AstraZeneca, which is headquartered in Cambridge, had discussed with officials “how we can contribute as a company to the pharmaceutical sector in the US, also how we can invest and how we can actually help deliver medicines to patients in America that are made in America”.
